Table 1.
Baselinea characteristics of children enrolled in TApHOD
| Characteristics | cART as the first ART regimen (n=1480) | Mono- or dual-therapy as the first ART regimen (n=272) | No ART (n=528) |
|---|---|---|---|
| Age, years | |||
| <1 | 112 (7.6) | 92 (33.8) | 36 (6.8) |
| 1-4 | 360 (24.3) | 109 (40.1) | 239 (45.3) |
| 5-12 | 930(62.8) | 64(23.5) | 233(44.2) |
| ≥13 | 78 (5.3) | 7 (2.6) | 20 (3.8) |
| Median (IQR) | 7.0 (3.9-9.9) | 2.1 (0.8-5.0) | 4.8 (2.7-7.8) |
| Male | 748 (50.5) | 141 (51.8) | 269 (51.0) |
| Perinatal infant antiretroviral prophylaxis | 136 (9.2) | 28 (10.3) | 51 (9.7) |
| Unknown | 500 (33.8) | 154 (56.6) | 357 (67.6) |
| Maternal antiretroviral prophylaxis | 119 (8.0) | 17 (6.3) | 46 (8.7) |
| Unknown | 490 (33.1) | 154 (56.6) | 360 (68.2) |
| CD4 percentage | |||
| ≤4 | 452 (30.5) | 30 (11.0) | 16 (3.1) |
| 5-14 | 427 (28.9) | 39 (14.3) | 44 (8.3) |
| 15-24 | 191 (12.9) | 64 (23.5) | 101 (19.1) |
| ≥25 | 68 (4.6) | 35 (12.9) | 69 (13.1) |
| Median (IQR) | 7.0 (3.9-9.9) | 17.0 (9.0-24.0) | 20.7 (14.0-26.0) |
| Unknown | 342 (23.1) | 104 (38.2) | 298 (56.4) |
| Median HIV RNA log10 copies/ml (IQR; percent available) | 5.3 (4.8-5.8; 38.1) | 5.8 (5.4-6.2; 14.3) | 5.1 (4.7-5.9; 6.6) |
| WHO clinical stagingb | |||
| Stage I | 100 (6.8) | 10 (3.7) | 28 (5.3) |
| Stage II | 306 (20.7) | 40 (14.7) | 89 (16.9) |
| Stage III | 411 (27.8) | 85 (31.3) | 140 (26.5) |
| Stage IV | 404 (27.3) | 38 (14.0) | 28 (5.3) |
| Unknown | 259 (17.5) | 99 (36.4) | 243 (46.0) |
| Severe anemiac | 54 (3.7) | 11(4.0) | 15 (2.8) |
| Unknown | 403 (27.2) | 145 (53.3) | 233 (44.1) |
| Mean hemoglobin, g/dl (SD) | 10.4 (1.7) | 10.1 (1.8) | 10.6 (1.8) |
| Weight-for-age z score,d median (IQR) (n=1121) | -2.7 (-4.0 to -1.5) | -2.1 (-3.6 to -1.1) | -2.2 (-3.6 to -1.2) |
| Height-for-age z score,e median (IQR) (n=1026) | -2.4 (-3.4 to -1.5) | -2.2 (-3.0 to -1.0) | -1.8 (-2.9 to -0.7) |
| BMI, median (IQR) (n=1010) | 14.4 (13.2-15.6) | 15.1(13.5-16.4) | 14.1 (12.8-15.4) |
ART – antiretroviral therapy; cART – combination ART; IQR – interquartile range; BMI – body mass index
a
Baseline was defined as date of ART initiation or date of enrollment if no ART was received. Data provided as n (%) unless otherwise noted.
b
Maximum stage at baseline was used.
c
Severe anemia was defined according to US guidelines (see Methods): hemoglobin <10 g/dL <21 days; <8 g/dL 22-35 days; <7 g/dL 36-56 days; <7.5 g/dL ≥57 days.
d
The 2000 US CDC growth curve was used.
e
The 2007 WHO growth curve was used.
f Refers to the first ART regimen.